Phase I trial of glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma showed immunological evidence and potential for improving overall survival Full Text
Clinical Cancer Research, 05/14/2012
Sawada Y et al. – GPC3–derived peptide vaccination was well–tolerated, and measurable immune responses and antitumor efficacy were noted. This is the first study to show that peptide–specific CTL frequency can be a predictive marker of overall survival in HCC patients receiving peptide vaccination.